QUEBEC CITY, QUEBEC - December 18, 2007 - Advitech Inc. ("Advitech" or the "Company") (TSX Venture Exchange: AVI) announces the conclusion of a definitive agreement for the distribution of DermylexTM on the Mexican market with Laboratorios Dermatológicos Darier S.A. de C.V. ("Darier"), a pharmaceutical leader in dermatology, specialized in the development and commercialization of prescription and cosmeceutical products.
"This is a breakthrough agreement for Advitech with Darier, a leading Mexican pharmaceutical company specializing in dermatology, as it constitutes our second commercial partnership with a pharmaceutical company specializing in dermatology," commented Mr. Renaud Beauchesne, President and Chief executive officer of Advitech.
"This is a significant partnership for Advitech as it further validates our clinical data and program on Dermylex™. It also reinforces our business strategy, which is to focus mainly on dermatology-oriented distributors, and it acknowledges the effectiveness of our patented XP-828L technological platform", added Mr. Beauchesne.
Mr. Fernando Ahumada, President and Chief executive officer of Darier added: "Laboratorios Dermatológicos Darier is the Mexican leader in dermatology and with the help of Dermylex™; we intend to increase our market share in psoriasis and collaborate with Advitech to investigate additional opportunities in dermatology in the Mexican market."
About Darier: www.darier.com.mx:
Darier is a vertically integrated specialty pharmaceutical company that researches, develops, manufactures and commercializes dermatology products for Mexico & Latin America. Darier is the market leader in dermatology with more than 13% in market share in Mexico. Darier'soffering includes a broad range of dermatological products for acne, atopic dermatitis, psoriasis, sunscreens, and skin cancer. Its strength lies on high product quality, product innovation and its privileged relationship with dermatologists and pediatricians cultivated over its 25-year history. Corporate headquarters are located in Mexico City, and research, development and manufacturing facilities are in Cuernavaca, Morelos, Mexico.
About Advitech Inc. www.advitech.com:
Advitech is a health sciences and technology company with a mission to discover and commercialize proprietary and evidence-based natural health products. Effective and safe, these products play a role in the prevention of immune-mediated inflammatory disorders, such as psoriasis and inflammatory bowel disease. Advitech produces Dermylex™ for the treatment of mild-to-moderate psoriasis.
Advitech has drawn up a research program to develop new applications related to wound healing. This development is derived from both its XP-828L technological platform and a new colostrums platform.
About Dermylex™ www.dermylex.com:
Dermylex™, developed by Advitech, is an oral natural health product formulated to improve mild-to-moderate psoriasis symptoms. Two clinical trials, including a 112-day, multi-center, double-blind, placebo-controlled trial with 84 patients, clinically proved the efficacy and safety of Dermylex™ for that type of psoriasis. Dermylex™ is currently available in Canada and the U.S. (as BioDerm, Dermalyx™), as well as in France and Belgium (as Psopax®).